(1-METHYL-1H-1,2,3-TRIAZOL-5-YL)METHANOL, 95.0%, 1g

1-(BROMOMETHYL)CYCLOPENTENE, 95.0%, 100mg

2-Fluoro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinoline-11-carboxylic acid, 1g

4-Bromo-2-(hydroxymethyl)phenol, 98.0%, 5g

5-Chloro-1H-pyrrolo[2,3-c]pyridine-3-carbonitrile, 97%, 100mg

7-Bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one, 97%, 500mg

Microliter syringe GASTIGHT® series 1700 Point type 2, 10 µl, 1701 RN, 1 piece

5-Bromo-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole, 96%, 250mg

5-Chloro-1H-pyrazole-4-carboxylic acid, 95.0%, 100mg

3-Aminoisonicotinamide, 97.0%, 10g

1,4-Dimethylpyrazole, 95.0%, 25g

4,5,6,7-Tetrahydropyrazolo[1,5-a]pyrazine dihydrochloride, 95.0%, 250mg

2-Methyl-4-(2-thienyl)-1,3-thiazole, 95%, 25g